Sergey V SUCHKOV
Head of the Department of Preventive, Personalized and Translational Medicine Institute of Personalized Medicine, International School of Personalized and Translational Medicine,
I. M. Sechenov First Moscow State Medical University (Moscow, Russia)
Professor at the Department of Clinical Immunology and Allergy, Faculty of Postgraduate Education,
A. I. Evdokimov Moscow State University of Medicine and Dentistry (Moscow, Russia)
DSc (medicine), professor
Areas of expertise:
preventive, precision and personalized medicine; immunology
ABOUT SCIENCE:
I decided to become a doctor because of my family history. Both of my parents were doctors. Then, I had amazing teachers at school. Another reason was my environment, both natural and human, that shaped my mentality. The last reason was my interest in Hi-Tech. These four factors played a key role in my career choice. I do not dream about discovering something new (you have to be a genius for that), but I am very interested in developing applied and bioengineering technologies. For example, a good idea is to design a project aimed to develop the national system of personalized medicine.
Ideally, a young scientist will go abroad, get unique education there an come back ready to create Hi-Tech products and teach the next generation of students who in their turn will develop Super Hi-Tech products in the future forming new markets or successfully competing with their rivals on the existing markets.
- Zemskov VM, Zemskov AM, Suchkov SV, Parshenkov AV. Tactic- and Strategy-affiliated Policy to Drive Clinical Immunology Ahead and to Secure the Future. Anatomy & Physiology: Current Research. 2016; 6 (3): 3–8.
- Chen Q, Varga M, Wang X, Haddad DJ, An S, Medzikovic L, Derakhshandeh R, Kostyushev DS, Zhang Y, Clifford BT, Luu E, Danforth OM, Rafikov R, Gong W, Black SM, Suchkov SV, et al. Overexpression of Nitric Oxide Synthase Restores Circulating Angiogenic Cell Function in Patients with Coronary Artery Disease: Implications for Autologous Cell Therapy for Myocardial Infarction. J Am Heart Assoc. 2016; 5 (1): 1–18.
- Zemskov VM, Alekseev AA, Gnatenko DA, Kozlova MN, Shishkina NS, Zemskov AM, Zhegalova IV, Bleykhman DA, Bahov NI, Suchkov SV. A Composite Biomarker Panel as a Highly Informative and Reliable Tool for Predicting Septic Complications. Jacobs Journal of Biomarkers. 2016; 2 (1): 1–10.
- Studneva M, Mandrik M, Song Sh, Tretyak E, Krasnyuk I, Yamada Y, Tukavin A, Ansari A, Kozlov I, Reading C, Ma Y, Krapfenbauer K, Svistunov A, Suchkov S. Strategic aspects of higher education reform to cultivate specialists in diagnostic and biopharma industry as applicable to Predictive, Preventive and Personalized Medicine as the Medicine of the Future. EPMA J. 2015; 6 (1): 18.
- Sadkovsky IA, Golubnitschaja O, Mandrik MA, Studneva MA, Abe H, Schroeder H, Antonova EN, Betsou F, Bodrova TA, Payne K, Suchkov SV. PPPM (Predictive, Preventive and Personalized Medicine) as a New Model of the National and International Healthcare Services and Thus a Promising Strategy to Prevent a Disease: From Basics to Practice. Int J Clin Med. 2014; 5 (14): 855–70.
- Suchkov S, Riding S, Rouz N, Notkins E, fon Gerrat M, Kriden Ld. Translyatsionnaya meditsina – mif ili real'nost'? Remedium. 2013; (6): 8–15. Russian.
- Suchkov SV, Gnatenko DA, Kostushev DS, Krynskiy SA, Paltsev MA. [Proteomics as a fundamental tool for subclinical screening, tests verification and assessment of applied therapy]. Annals of the Russian academy of medical sciences. 2013; (1): 65–71. Russian.
- Bodrova TA, Kostushev DS, Antonova EN, Gnatenko DA, Bocharova MO, Lopukhin YuO, Paltsev MA, Suchkov SV. [Introducn into PPPM: experience of the past and tomorrow ,s reality]. Annals of the Russian academy of medical sciences. 2013; (1): 58–64.
- Bodrova TA, Kostyushev DS, Antonova EN, Slavin Sh, Gnatenko DA, Bocharova MO, Legg M, Pozzilli P, Suchkov SV. Introduction into PPPM as a new paradigm of public health service: an integrative view. EPMA J. 2012; 3 (1): 16.
- Gabibov AA, Paltsev MA, Suchkov SV. Antibody-associated proteolysis in surveillance of autoimmune demyelination: clinical and preclinical issues. Future Neurology. 2011; 6 (3): 303–5.
